Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents

Morie Gertz, Evangelos Terpos, Angela Dispenzieri, Shaji K Kumar, Rupin A. Shah, Robert Orlowski, Efstathios Kastritis, Meletios A. Dimopoulos, Jatin Shah

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities.

Original languageEnglish (US)
Pages (from-to)1723-1726
Number of pages4
JournalLeukemia and Lymphoma
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2015

    Fingerprint

Keywords

  • Acute leukemia
  • Hypomethylating agents
  • Lenalidomide
  • Multiple myeloma
  • Myelodysplasia
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this